



ADULT MEDICATION GUIDELINE

Verapamil

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

Injection: [Formulary: Restricted](#)

Others: [Formulary: Unrestricted](#)

Medication Class

Calcium Channel Blocker

Presentation

Tablet (immediate release): 40mg

Tablet (controlled release): 180mg, 240mg

Injection (ampoule): 5mg/2mL

Storage

Store at room temperature, below 25°C

Dose

Hypertension

Oral:

Immediate release tablet: initially 80mg 2 or 3 times daily; maintenance 160 mg 2 or 3 times daily.

Controlled release tablet: initially 120–180mg once daily; maintenance 240 mg once daily; maximum 240 mg twice daily. Give daily doses >240 mg in two doses.

SVT, AF or atrial flutter

Oral:

Immediate release tablet: initially 40–80mg 2 or 3 times daily; maintenance 160 mg 2 or 3 times daily.

Controlled release tablet: initially 120–240 mg once daily; maximum 240 mg twice daily. Give daily doses >240 mg in two doses.

IV injection:

2.5–10 mg over two to three minutes.

Angina

Oral:

Immediate release tablet: initially 80 mg 2 or 3 times daily; maintenance 160 mg 2 or 3 times daily.

Controlled release tablet: initially 180–240 mg once daily; maximum 240 mg twice daily. Give daily doses >240 mg in two doses.

Administration

Refer to the Australian Injectable Drugs Handbook

Oral

Take with or without food. Swallow controlled release tablets whole.

IV infusion.

Dilution: Dilute with Glucose 5% or Sodium Chloride 0.9%.

Administration: Infuse at a rate of 5–10 mg/hour.

IV injection

Dilution: Dilute one ampoule to 10 mL with Sodium Chloride 0.9%. Concentration is 0.5 mg/mL

Administration: Inject SLOWLY over at least 2 minutes (at least 3 minutes in older patients).

Monitoring

ECG

Blood Pressure

Pregnancy

1st Trimester: Monitoring required

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Considered safe to use

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Related Policies, Procedures & Guidelines









[Pre-operative Medication Management](#)

References

Australian Medicines Handbook. Verapamil. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Oct 13]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Verapamil. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Oct 13]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Verapamil. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Oct 13]. Available from: <http://aidh.hcn.com.au>

Keywords	Verapamil, isoptin, AF, SVT, atrial flutter, hypertension, angina, calcium channel blocker, CCB, antiarrhythmic				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	Dec 2017	Last Reviewed:	Nov 2021	Review Date:	Dec 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	Jan 2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.